Back to Search
Start Over
Parkinson mice show functional and molecular changes in the gut long before motoric disease onset
- Source :
- Molecular neurodegeneration, Molecular Neurodegeneration, Molecular Neurodegeneration, Vol 16, Iss 1, Pp 1-23 (2021)
- Publication Year :
- 2021
-
Abstract
- Background There is increasing evidence that Parkinson’s disease (PD) might start in the gut, thus involving and compromising also the enteric nervous system (ENS). At the clinical onset of the disease the majority of dopaminergic neurons in the midbrain is already destroyed, so that the lack of early biomarkers for the disease represents a major challenge for developing timely treatment interventions. Here, we use a transgenic A30P-α-synuclein-overexpressing PD mouse model to identify appropriate candidate markers in the gut before hallmark symptoms begin to manifest. Methods Based on a gait analysis and striatal dopamine levels, we defined 2-month-old A30P mice as pre-symptomatic (psA30P), since they are not showing any motoric impairments of the skeletal neuromuscular system and no reduced dopamine levels, but an intestinal α-synuclein pathology. Mice at this particular age were further used to analyze functional and molecular alterations in both, the gastrointestinal tract and the ENS, to identify early pathological changes. We examined the gastrointestinal motility, the molecular composition of the ENS, as well as the expression of regulating miRNAs. Moreover, we applied A30P-α-synuclein challenges in vitro to simulate PD in the ENS. Results A retarded gut motility and early molecular dysregulations were found in the myenteric plexus of psA30P mice. We found that i.e. neurofilament light chain, vesicle-associated membrane protein 2 and calbindin 2, together with the miRNAs that regulate them, are significantly altered in the psA30P, thus representing potential biomarkers for early PD. Many of the dysregulated miRNAs found in the psA30P mice are reported to be changed in PD patients as well, either in blood, cerebrospinal fluid or brain tissue. Interestingly, the in vitro approaches delivered similar changes in the ENS cultures as seen in the transgenic animals, thus confirming the data from the mouse model. Conclusions These findings provide an interesting and novel approach for the identification of appropriate biomarkers in men.
- Subjects :
- 0301 basic medicine
Parkinson's disease
Neurology
Protein-and miRNA biomarkers
Gastrointestinal Diseases
alpha-synuclein
Enteric Nervous System
Mice
0302 clinical medicine
subcellular-localization
oxidative stress
alzheimers-disease
Myenteric plexus
Gastrointestinal tract
Dopaminergic
medicine.drug
Research Article
medicine.medical_specialty
Prodromal Symptoms
03 medical and health sciences
Cellular and Molecular Neuroscience
lipid-peroxidation
Parkinsonian Disorders
Dopamine
enteric nervous-system
medicine
Animals
RC346-429
Molecular Biology
wild-type
Gastrointestinal motility
business.industry
RC952-954.6
medicine.disease
Molecular medicine
Mice, Inbred C57BL
030104 developmental biology
Geriatrics
substantia-nigra
Immunology
parkinson's disease
Parkinson’s disease
Enteric nervous system
Neurology. Diseases of the nervous system
Neurology (clinical)
Human medicine
business
030217 neurology & neurosurgery
binding protein calretinin
Early onset
myenteric plexus
Subjects
Details
- Language :
- English
- ISSN :
- 17501326
- Database :
- OpenAIRE
- Journal :
- Molecular neurodegeneration
- Accession number :
- edsair.doi.dedup.....5851d31da61184256eceb17b2012927c